This portal is intended for Healthcare Professionals outside of the UK and USA.

Skip to main content
Together, we’ll see new horizons

Prepare for an immersive experience at APVRS 2026 by exploring the Roche agenda and our distinguished lineup of speakers. We will delve into the latest clinical insights and therapeutic advancements. Stay ahead of the curve in retinal health by connecting with global leaders and participating in our dedicated sessions.

Discover the latest Roche scientific information

Attend high-impact Scientific Presentations and browse breakthrough Posters that highlight the latest clinical and scientific advances.

Date

Time 

Indication

Topic

Presenter

Venue

 

 

DME

Improved Vascular Stability Biomarkers With Faricimab Vs Aflibercept 2 mg Using Automated Quantification On Ultra-Widefield Fluorescein Angiography (UWFA), Color Fundus Photography (CFP) and Optical Coherence Tomography (OCT)

Hemal Mehta

 

 

 

DME

Impact of Baseline Subretinal Fluid (SRF) on Treatment Outcomes in Diabetic Macular Edema (DME): Analysis of the Phase 3 YOSEMITE and RHINE Trials

Jeeyun Ahn

 

 

 

nAMD

Better Visual Outcomes With Faricimab vs Aflibercept 2 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration (nAMD) Who Had Small Lesions: A TENAYA/LUCERNE Post Hoc Analysis

DK Hwang

 

 

 

nAMD

Reduction in Subretinal Hyperreflective Material (SHRM) With Faricimab vs Aflibercept 2 mg in Treatment-Naïve Neovascular Age-related Macular Degeneration (nAMD)

SeJoon Woo

 

 

 

nAMD

Faricimab for Polypoidal Choroidal Vasculopathy (PCV): Two-Year Results From the SALWEEN Trial

Gemmy Cheung

 

 

 

RWD

One-Year Outcomes of Faricimab Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) From a Global, Prospective Observational Study: The VOYAGER Study

Robyn Guymer

 

 

 

RWD

Anatomical Outcomes Of Faricimab In Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): 6-month Real-world Imaging From The VOYAGER Study

Adrian Koh

 

 

 

RWD

Effectiveness and Safety of Faricimab in Eyes With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years: Results From the UK Faricimab Real-World Evidence (FARWIDE) Study

Kenneth Fong

 

 

 

RWD

3-Month Data of Faricimab in Treatment-Naïve Patients With Macular Edema Associated With Diabetic Retinopathy or Retinal Vein Occlusion: An Interim Analysis of the Farseeing Study in China

Ling Yuan

 

 

 

RWD

Effectiveness and Safety of Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration in China: 3-Month Results in a Real-World Study

Rongrong Zhu

 

Date Time Indication Topic Presenter Venue

DME

Improved Vascular Stability Biomarkers With Faricimab Vs Aflibercept 2 mg Using Automated Quantification On Ultra-Widefield Fluorescein Angiography (UWFA), Color Fundus Photography (CFP) and Optical Coherence Tomography (OCT)

Hemal Mehta, AU

DME

Impact of Baseline Subretinal Fluid (SRF) on Treatment Outcomes in Diabetic Macular Edema (DME): Analysis of the Phase 3 YOSEMITE and RHINE Trials

Jeeyun Ahn, KR

nAMD

Better Visual Outcomes With Faricimab vs Aflibercept 2 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration (nAMD) Who Had Small Lesions: A TENAYA/LUCERNE Post Hoc Analysis

DK Hwang, TW

nAMD

Reduction in Subretinal Hyperreflective Material (SHRM) With Faricimab vs Aflibercept 2 mg in Treatment-Naïve Neovascular Age-related Macular Degeneration (nAMD)

SeJoon Woo, KR

nAMD

Faricimab for Polypoidal Choroidal Vasculopathy (PCV): Two-Year Results From the SALWEEN Trial

Gemmy Cheung, SG

RWD

One-Year Outcomes of Faricimab Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) From a Global, Prospective Observational Study: The VOYAGER Study

Robyn Guymer, AU

RWD

Anatomical Outcomes Of Faricimab In Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): 6-month Real-world Imaging From The VOYAGER Study

Adrian Koh, SG

RWD

Effectiveness and Safety of Faricimab in Eyes With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years: Results From the UK Faricimab Real-World Evidence (FARWIDE) Study

Kenneth Fong, MY

RWD

3-Month Data of Faricimab in Treatment-Naïve Patients With Macular Edema Associated With Diabetic Retinopathy or Retinal Vein Occlusion: An Interim Analysis of the Farseeing Study in China

Ling Yuan

RWD

Effectiveness and Safety of Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration in China: 3-Month Results in a Real-World Study

Rongrong Zhu

DME

DME

nAMD

nAMD

nAMD

RWD

RWD

RWD

RWD

RWD

Improved Vascular Stability Biomarkers With Faricimab Vs Aflibercept 2 mg Using Automated Quantification On Ultra-Widefield Fluorescein Angiography (UWFA), Color Fundus Photography (CFP) and Optical Coherence Tomography (OCT)

Impact of Baseline Subretinal Fluid (SRF) on Treatment Outcomes in Diabetic Macular Edema (DME): Analysis of the Phase 3 YOSEMITE and RHINE Trials

Better Visual Outcomes With Faricimab vs Aflibercept 2 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration (nAMD) Who Had Small Lesions: A TENAYA/LUCERNE Post Hoc Analysis

Reduction in Subretinal Hyperreflective Material (SHRM) With Faricimab vs Aflibercept 2 mg in Treatment-Naïve Neovascular Age-related Macular Degeneration (nAMD)

Faricimab for Polypoidal Choroidal Vasculopathy (PCV): Two-Year Results From the SALWEEN Trial

One-Year Outcomes of Faricimab Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) From a Global, Prospective Observational Study: The VOYAGER Study

Anatomical Outcomes Of Faricimab In Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): 6-month Real-world Imaging From The VOYAGER Study

Effectiveness and Safety of Faricimab in Eyes With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years: Results From the UK Faricimab Real-World Evidence (FARWIDE) Study

3-Month Data of Faricimab in Treatment-Naïve Patients With Macular Edema Associated With Diabetic Retinopathy or Retinal Vein Occlusion: An Interim Analysis of the Farseeing Study in China

Effectiveness and Safety of Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration in China: 3-Month Results in a Real-World Study

Hemal Mehta, AU

Jeeyun Ahn, KR

DK Hwang, TW

SeJoon Woo, KR

Gemmy Cheung, SG

Robyn Guymer, AU

Adrian Koh, SG

Kenneth Fong, MY

Ling Yuan

Rongrong Zhu

DME

DME

nAMD

nAMD

nAMD

RWD

RWD

RWD

RWD

RWD

Improved Vascular Stability Biomarkers With Faricimab Vs Aflibercept 2 mg Using Automated Quantification On Ultra-Widefield Fluorescein Angiography (UWFA), Color Fundus Photography (CFP) and Optical Coherence Tomography (OCT)

Impact of Baseline Subretinal Fluid (SRF) on Treatment Outcomes in Diabetic Macular Edema (DME): Analysis of the Phase 3 YOSEMITE and RHINE Trials

Better Visual Outcomes With Faricimab vs Aflibercept 2 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration (nAMD) Who Had Small Lesions: A TENAYA/LUCERNE Post Hoc Analysis

Reduction in Subretinal Hyperreflective Material (SHRM) With Faricimab vs Aflibercept 2 mg in Treatment-Naïve Neovascular Age-related Macular Degeneration (nAMD)

Faricimab for Polypoidal Choroidal Vasculopathy (PCV): Two-Year Results From the SALWEEN Trial

One-Year Outcomes of Faricimab Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) From a Global, Prospective Observational Study: The VOYAGER Study

Anatomical Outcomes Of Faricimab In Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): 6-month Real-world Imaging From The VOYAGER Study

Effectiveness and Safety of Faricimab in Eyes With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years: Results From the UK Faricimab Real-World Evidence (FARWIDE) Study

3-Month Data of Faricimab in Treatment-Naïve Patients With Macular Edema Associated With Diabetic Retinopathy or Retinal Vein Occlusion: An Interim Analysis of the Farseeing Study in China

Effectiveness and Safety of Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration in China: 3-Month Results in a Real-World Study

Hemal Mehta, AU

Jeeyun Ahn, KR

DK Hwang, TW

SeJoon Woo, KR

Gemmy Cheung, SG

Robyn Guymer, AU

Adrian Koh, SG

Kenneth Fong, MY

Ling Yuan

Rongrong Zhu

Date
Time
Indication

DME

DME

nAMD

nAMD

nAMD

RWD

RWD

RWD

RWD

RWD

Topic

Improved Vascular Stability Biomarkers With Faricimab Vs Aflibercept 2 mg Using Automated Quantification On Ultra-Widefield Fluorescein Angiography (UWFA), Color Fundus Photography (CFP) and Optical Coherence Tomography (OCT)

Impact of Baseline Subretinal Fluid (SRF) on Treatment Outcomes in Diabetic Macular Edema (DME): Analysis of the Phase 3 YOSEMITE and RHINE Trials

Better Visual Outcomes With Faricimab vs Aflibercept 2 mg in Patients With Treatment-Naïve Neovascular Age-Related Macular Degeneration (nAMD) Who Had Small Lesions: A TENAYA/LUCERNE Post Hoc Analysis

Reduction in Subretinal Hyperreflective Material (SHRM) With Faricimab vs Aflibercept 2 mg in Treatment-Naïve Neovascular Age-related Macular Degeneration (nAMD)

Faricimab for Polypoidal Choroidal Vasculopathy (PCV): Two-Year Results From the SALWEEN Trial

One-Year Outcomes of Faricimab Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) From a Global, Prospective Observational Study: The VOYAGER Study

Anatomical Outcomes Of Faricimab In Patients With Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME): 6-month Real-world Imaging From The VOYAGER Study

Effectiveness and Safety of Faricimab in Eyes With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years: Results From the UK Faricimab Real-World Evidence (FARWIDE) Study

3-Month Data of Faricimab in Treatment-Naïve Patients With Macular Edema Associated With Diabetic Retinopathy or Retinal Vein Occlusion: An Interim Analysis of the Farseeing Study in China

Effectiveness and Safety of Faricimab in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration in China: 3-Month Results in a Real-World Study

Presenter

Hemal Mehta, AU

Jeeyun Ahn, KR

DK Hwang, TW

SeJoon Woo, KR

Gemmy Cheung, SG

Robyn Guymer, AU

Adrian Koh, SG

Kenneth Fong, MY

Ling Yuan

Rongrong Zhu

Venue

Date

Time 

Indication

Topic

Presenter

Venue

 

 

UME

Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials

Lyndell Lim

 

 

 

UME

A Synthesis of Real‑World Evidence From the J‑CAT Studies: Treatment Patterns, Complication/Adverse Event Risks, and Economic Burden in Non‑Infectious Uveitis (NIU) in Japan

Sentro Kusuhara

 

Date Time Indication Topic Presenter Venue

UME

Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials

Lyndell Lim, AU

UME

A Synthesis of Real‑World Evidence From the J‑CAT Studies: Treatment Patterns, Complication/Adverse Event Risks, and Economic Burden in Non‑Infectious Uveitis (NIU) in Japan

Sentro Kusuhara, JP

UME

UME

Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials

A Synthesis of Real‑World Evidence From the J‑CAT Studies: Treatment Patterns, Complication/Adverse Event Risks, and Economic Burden in Non‑Infectious Uveitis (NIU) in Japan

Lyndell Lim, AU

Sentro Kusuhara, JP

UME

UME

Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials

A Synthesis of Real‑World Evidence From the J‑CAT Studies: Treatment Patterns, Complication/Adverse Event Risks, and Economic Burden in Non‑Infectious Uveitis (NIU) in Japan

Lyndell Lim, AU

Sentro Kusuhara, JP

Date
Time
Indication

UME

UME

Topic

Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: Pooled Results from the Phase 3 MEERKAT and SANDCAT Trials

A Synthesis of Real‑World Evidence From the J‑CAT Studies: Treatment Patterns, Complication/Adverse Event Risks, and Economic Burden in Non‑Infectious Uveitis (NIU) in Japan

Presenter

Lyndell Lim, AU

Sentro Kusuhara, JP

Venue

Date

Time 

Indication

Topic

Presenter

Venue

 

 

nAMD

Interim analysis of the Belvedere nAMD study: summary of PDS treatment in eyes with high injection burden

Anthony Kwan

 

 

 

nAMD

Archway 5yr nAMD LTO Fluid presence

Min Sagong

 

 

 

DME

PAGODA EOS

Yin Shiou Hwang

 

Date Time Indication Topic Presenter Venue

nAMD

Interim analysis of the Belvedere nAMD study: summary of PDS treatment in eyes with high injection burden

Anthony Kwan, AU

nAMD

Archway 5yr nAMD LTO Fluid presence

Min Sagong, KR

DME

PAGODA EOS

Yin Shiou Hwang, TW

nAMD

nAMD

DME

Interim analysis of the Belvedere nAMD study: summary of PDS treatment in eyes with high injection burden

Archway 5yr nAMD LTO Fluid presence

PAGODA EOS

Anthony Kwan, AU

Min Sagong, KR

Yin Shiou Hwang, TW

nAMD

nAMD

DME

Interim analysis of the Belvedere nAMD study: summary of PDS treatment in eyes with high injection burden

Archway 5yr nAMD LTO Fluid presence

PAGODA EOS

Anthony Kwan, AU

Min Sagong, KR

Yin Shiou Hwang, TW

Date
Time
Indication

nAMD

nAMD

DME

Topic

Interim analysis of the Belvedere nAMD study: summary of PDS treatment in eyes with high injection burden

Archway 5yr nAMD LTO Fluid presence

PAGODA EOS

Presenter

Anthony Kwan, AU

Min Sagong, KR

Yin Shiou Hwang, TW

Venue

nAMD Faricimab Symposium

The nAMD Winning Strategy with Vabysmo: Looking Beyond VEGF-A Inhibition

Date: 29th Aug | Time: 13:00-14:00 |

Room: Arena 1

Add to Calendar
Title Speaker

The Current nAMD Treatment Landscape and Unmet Needs

Adrian Koh (Chair; Singapore)

Dual Pathway Inhibition for Rapid Drying

Patricio Schlottmann (Argentina)

Rapid Drying for Disease Control

Tai-Chi Lin (Taiwan)

Disease Control for Extended Durability

Paul Mitchell (Australia)

Closing Remarks

Adrian Koh (Chair; Singapore)

The Current nAMD Treatment Landscape and Unmet Needs

Dual Pathway Inhibition for Rapid Drying

Rapid Drying for Disease Control

Disease Control for Extended Durability

Closing Remarks

Adrian Koh (Chair; Singapore)

Patricio Schlottmann (Argentina)

Tai-Chi Lin (Taiwan)

Paul Mitchell (Australia)

Adrian Koh (Chair; Singapore)

The Current nAMD Treatment Landscape and Unmet Needs

Dual Pathway Inhibition for Rapid Drying

Rapid Drying for Disease Control

Disease Control for Extended Durability

Closing Remarks

Adrian Koh (Chair; Singapore)

Patricio Schlottmann (Argentina)

Tai-Chi Lin (Taiwan)

Paul Mitchell (Australia)

Adrian Koh (Chair; Singapore)

Title

The Current nAMD Treatment Landscape and Unmet Needs

Dual Pathway Inhibition for Rapid Drying

Rapid Drying for Disease Control

Disease Control for Extended Durability

Closing Remarks

Speaker

Adrian Koh (Chair; Singapore)

Patricio Schlottmann (Argentina)

Tai-Chi Lin (Taiwan)

Paul Mitchell (Australia)

Adrian Koh (Chair; Singapore)

Adrian Koh

 

Dr. Adrian Koh is a highly accomplished ophthalmologist, serving as a Founding Partner at Eye & Retina Surgeons, Director of Retinal Centre International, and Vice-President of the International Retinal Foundation. His extensive professional background includes fellowships at Moorfields Eye Hospital and the Jules Stein Eye Institute, and past roles such as Deputy Head of the Retina Research Group at SERI. Dr. Koh’s expertise covers a wide range of conditions, including degenerative macular diseases, inherited retinal diseases (like retinitis pigmentosa), and retinal vascular diseases. He is a diagnostic specialist who receives regional referrals for complex cases and is a leader in advanced treatments for macular degeneration and severe diabetic retinopathy, utilizing methods such as photodynamic therapy, anti-VEGF therapy, laser techniques (PASCAL system), and intravitreal adjunctive therapies.

Patricio Schlottmann

 

Dr. Patricio G. Schlottmann, MD, is an ophthalmologist and researcher in Buenos Aires, Argentina, serving as the Director of the Research Department at the Charles Research Center. He earned his MD from the University of Buenos Aires and completed specialized training and a research fellowship at Moorfields Eye Hospital in London. Dr. Schlottmann has demonstrated leadership by heading over 35 clinical research studies and founding the RIO LATAM initiative to enhance ophthalmology research collaboration across Argentina, Brazil, and Colombia. He is a prolific author, with over 60 publications and more than 4000 citations, and is actively involved as a peer reviewer, an editorial board member for prominent medical journals, and the vice president of the Argentinean Vitreous Retina Society.

Tai-Chi Lin

 

Dr. Tai-Chi Lin is the Director of the Vitreoretinal division at Taipei Veterans General Hospital and an Associate Professor at National Yang Ming Chiao Tung University. His primary research focuses on stem cell-based therapy and retinal diseases, and his surgical expertise includes macular, diabetic, complex retinal detachments, and cataract surgery. He is a prolific author, having published over 80 peer-reviewed manuscripts and delivered more than 50 talks internationally and in Taiwan.  In addition, his dedication to rural public health over the past five years is notable, combining traditional screening with innovative telemedicine to screen diabetic patients for retinopathy, prevent blindness, and ease the burden on the local healthcare system.

Paul Mitchell

 

Prof. Paul Mitchell is an Emeritus Professor of Ophthalmology at the University of Sydney and a Member of the Centre For Vision Research at the Westmead Institute for Medical Research. He is a leading expert in macular degeneration, publishing extensively on the management of age-related macular degeneration (AMD), diabetic, and other vascular retinopathies, and co-authoring over 1,100 scientific publications. His contributions have been recognized with the 2004 Association of International Glaucoma Societies Award, his appointment as Trustee for the Clinical & Epidemiologic Research section of the Association for Research in Vision and Ophthalmology (ARVO) in 2007, and the Order of Australia (AO) in 2018 for his research.

DMO Faricimab Symposium

The DMO evidence area: Where data meets clinical practice

Date: 28th Aug | Time: 12:00-13:00

Room: Arena 1

Add to Calendar
Title Speaker

The Patient Behind the Pathology

Anthony Kwan (Chair, Australia)

The Promise Delivered: 4 Years of Clarity

Timothy Lai (Hong Kong)

The Illusion of Durability

Colin Tan (Singapore)

Beyond Simple Drying: Structural Remodelling

Christiana Dinah (UK)

Closing Remarks

Anthony Kwan (Chair, Australia)

The Patient Behind the Pathology

The Promise Delivered: 4 Years of Clarity

The Illusion of Durability

Beyond Simple Drying: Structural Remodelling

Closing Remarks

Anthony Kwan (Chair, Australia)

Timothy Lai (Hong Kong)

Colin Tan (Singapore)

Christiana Dinah (UK)

Anthony Kwan (Chair, Australia)

The Patient Behind the Pathology

The Promise Delivered: 4 Years of Clarity

The Illusion of Durability

Beyond Simple Drying: Structural Remodelling

Closing Remarks

Anthony Kwan (Chair, Australia)

Timothy Lai (Hong Kong)

Colin Tan (Singapore)

Christiana Dinah (UK)

Anthony Kwan (Chair, Australia)

Title

The Patient Behind the Pathology

The Promise Delivered: 4 Years of Clarity

The Illusion of Durability

Beyond Simple Drying: Structural Remodelling

Closing Remarks

Speaker

Anthony Kwan (Chair, Australia)

Timothy Lai (Hong Kong)

Colin Tan (Singapore)

Christiana Dinah (UK)

Anthony Kwan (Chair, Australia)

Anthony Kwan
 

Associate Professor Anthony Kwan is a highly accomplished Vitreoretinal surgeon, currently serving as the Director of Vitreoretinal Service at the Queensland Eye Institute. He specializes in a wide range of retinal and macular diseases, including age-related macular degeneration and diabetic retinopathy, and performs cataract and vitrectomy operations. Prof. Kwan also has extensive research experience, particularly in experimental retinal transplantation, conducts clinical trials, and has secured grants from organizations like NHMRC and MDFA. Furthermore, he has held significant leadership roles, including Head of Ophthalmology at Mater Hospital and Chair of the Macular Disease Foundation Australia’s Research Committee since 2020.

Colin Tan

 

A/Prof Colin Tan is an Associate Professor of Ophthalmology at the Lee Kong Chian School of Medicine and Duke-NUS Medical School, and a Senior Consultant and Head of the Fundus Image Reading Center at the National Healthcare Group Eye Institute. His distinguished career includes a Fellowship in Medical Retina and Retinal Imaging and is marked by substantial academic contributions, having authored over 300 publications and several book chapters, and receiving major accolades like the National Medical Research Council Transition Award and the American Academy of Ophthalmology Achievement Award for his research on tomography angiography and optical coherence tomography.

Christiana Dinah

 

Dr Christiana Dinah is the macula service and research lead at Central Middlesex Hospital. She is the director for research and innovation at LNWH and the director for the newly established NIHR North West London Commercial Research Delivery Centre. She is also honorary senior clinical lecturer at Imperial College, London. She completed her medical retina fellowship at Moorfields Eye Hospital and then became a consultant at Central Middlesex Hospital, where she set up the award-winning research department. Dr Dinah has served as chief investigator or principal investigator in over 25 clinical trials, from Phase I to Phase IV. She was an expert member of the NICE diabetic retinopathy guidelines committee published in 2024 and is a member of Council of the Oxford Ophthalmological Congress. Her research interests are in AMD and retinovascular diseases, and she is passionate about patient-centric research design and inclusion in clinical research.

Timothy Lai

 

Prof. Timothy Lai, currently Clinical Professor (Honorary) at CUHK and Director of the 2010 Retina and Macula Centre, Hong Kong, specializes in the medical and surgical management of various retinal diseases. His significant academic career is marked by over 300 publications, a Scopus h-index of 69, and being named the world’s no.1 expert in choroidal neovascularization by Expertscape in 2022 and 2023. Prof. Lai’s international recognition is further evidenced by prestigious awards like the APAO Nakajima Award and his extensive leadership roles, including Vice President of the APVRS and President of the HKVRS, alongside service on over 10 international ophthalmic journal editorial boards.

Roche Ophthalmology Pipeline Symposium

Looking Beyong Injections: Addressing the Treatment Challenge of nAMD

Date: 28th Aug | Time: 17:30-18:00

Room: Arena 1

Add to Calendar
Title Speaker

Opening Remarks

The Evolving Treatment Landscape

Treatment burden and why it matters, overview of competitor landscape, and introduction to the PDS

Andrew Chang (Chair; Australia)

Through the Patient’s Eyes: Interview

I-Van Ho (Australia)

Continuous Drug Delivery: The Future of Sustainable Retinal Health

The Uninterrupted View: 5 to 7 Years of Continuous Delivery in nAMD (Long-Term Efficacy and Safety)

Yi-Ting Hsieh (Taiwan)

Confidence in Care: Surgery and Safety

Patient selection and ideal PDS candidates; overview of surgical and refill-exchange steps

Nancy Holekamp (Roche)

Cultivating Trust Through Patient-Centred Excellence: Panel Discussion with Q&A

Reducing high-treatment burden in nAMD

All

Shaping the Future: Unlocking the Full Potential of the Port Delivery Platform

Roche's commitment to bringing innovative treatments to patients

Andrew Chang (Chair; Australia)

Opening Remarks

The Evolving Treatment Landscape

Treatment burden and why it matters, overview of competitor landscape, and introduction to the PDS

Through the Patient’s Eyes: Interview

Continuous Drug Delivery: The Future of Sustainable Retinal Health

The Uninterrupted View: 5 to 7 Years of Continuous Delivery in nAMD (Long-Term Efficacy and Safety)

Confidence in Care: Surgery and Safety

Patient selection and ideal PDS candidates; overview of surgical and refill-exchange steps

Cultivating Trust Through Patient-Centred Excellence: Panel Discussion with Q&A

Reducing high-treatment burden in nAMD

Shaping the Future: Unlocking the Full Potential of the Port Delivery Platform

Roche's commitment to bringing innovative treatments to patients

Andrew Chang (Chair; Australia)

I-Van Ho (Australia)

Yi-Ting Hsieh (Taiwan)

Nancy Holekamp (Roche)

All

Andrew Chang (Chair; Australia)

Opening Remarks

The Evolving Treatment Landscape

Treatment burden and why it matters, overview of competitor landscape, and introduction to the PDS

Through the Patient’s Eyes: Interview

Continuous Drug Delivery: The Future of Sustainable Retinal Health

The Uninterrupted View: 5 to 7 Years of Continuous Delivery in nAMD (Long-Term Efficacy and Safety)

Confidence in Care: Surgery and Safety

Patient selection and ideal PDS candidates; overview of surgical and refill-exchange steps

Cultivating Trust Through Patient-Centred Excellence: Panel Discussion with Q&A

Reducing high-treatment burden in nAMD

Shaping the Future: Unlocking the Full Potential of the Port Delivery Platform

Roche's commitment to bringing innovative treatments to patients

Andrew Chang (Chair; Australia)

I-Van Ho (Australia)

Yi-Ting Hsieh (Taiwan)

Nancy Holekamp (Roche)

All

Andrew Chang (Chair; Australia)

Title

Opening Remarks

The Evolving Treatment Landscape

Treatment burden and why it matters, overview of competitor landscape, and introduction to the PDS

Through the Patient’s Eyes: Interview

Continuous Drug Delivery: The Future of Sustainable Retinal Health

The Uninterrupted View: 5 to 7 Years of Continuous Delivery in nAMD (Long-Term Efficacy and Safety)

Confidence in Care: Surgery and Safety

Patient selection and ideal PDS candidates; overview of surgical and refill-exchange steps

Cultivating Trust Through Patient-Centred Excellence: Panel Discussion with Q&A

Reducing high-treatment burden in nAMD

Shaping the Future: Unlocking the Full Potential of the Port Delivery Platform

Roche's commitment to bringing innovative treatments to patients

Speaker

Andrew Chang (Chair; Australia)

I-Van Ho (Australia)

Yi-Ting Hsieh (Taiwan)

Nancy Holekamp (Roche)

All

Andrew Chang (Chair; Australia)

Andrew Chang
 

Professor Andrew Chang is a prominent Australian ophthalmologist and vitreoretinal surgeon who serves as the Medical Director of the Sydney Retina Clinic and the Head of Ophthalmology at the Sydney Eye Hospital. He graduated from the University of Sydney Medical School, earned a PhD for retinal research conducted in both Australia and the USA, and completed advanced retinal fellowships at the Royal Victorian Eye and Ear Hospital. Highly active in academia and health policy, he holds a Conjoint Professorship at UNSW, acts as a clinician advisor to the Australian Department of Health and the TGA, and holds prominent international leadership roles including Secretary General of the Asia-Pacific Vitreoretinal Society. For his extensive contributions to blindness prevention, clinical research, and ophthalmic education, Professor Chang was appointed a Member of the Order of Australia (AM).

I-Van Ho

 

Professor I-Van Ho is a highly qualified Vitreoretinal Surgeon and Macular Disease Specialist based in Australia, holding an MBBS, MPH, and PhD. After completing his ophthalmology residency at the Sydney Eye Hospital, he undertook advanced international fellowship training in Canada and New York. He currently serves as a Professor of Ophthalmology at Macquarie University and is a senior consultant at the Sydney Eye Hospital, where he also directs the Vitreoretinal Fellowship program. His specialized clinical expertise focuses on small incision vitrectomy surgery, advanced retinal imaging, and the medical and surgical management of macular and vitreoretinal diseases. 

Nancy Holekamp
 

Nancy M. Holekamp, MD was Director of Retina Services at the Pepose Vision Institute in St. Louis, Missouri from 2011 to 2022. Prior, she was Professor of Clinical Ophthalmology at the Washington University School of Medicine in St. Louis, Missouri from 2009 to 2020. She has been a principal investigator in more than 40 national clinical trials dealing with age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy. Her efforts in research have resulted in over 100 peer-reviewed publications, 22 book chapters, and more than 150 speaking invitations. She was Visiting Professor at Roche in 2023 and is now a Principal Global Medical Science Lead at Roche.

Yi-Ting Hsieh

 

Yi-Ting Hsieh, MD, PhD is Clinical Professor at National Taiwan University and Chair of Ophthalmology at NTU Hospital, Hsin-Chu Branch. His work bridges cutting-edge research and clinical care, focusing on diabetic retinopathy, vitreomacular interface diseases, age-related macular degeneration, hydroxychloroquine retinopathy, ocular imaging, and the application of artificial intelligence. He has published over 180 SCI-indexed journal articles and received several international honors, including the Best Free Paper Award (APVRS, 2018), Best Video Award (APVRS, 2019), and Best Free Paper Award (APAO, 2021). Dr. Hsieh has served as faculty at numerous international congresses, including the Retina World Congress, APAO, and APVRS. As the inventor of the AI diagnostic platforms VeriSee DR and VeriSee AMD, he has advanced the application of artificial intelligence in ophthalmology.

Contact Us

Please review the Product Information (PI) before prescribing, available at www.roche-australia.com/productinfo/vabysmo. VABYSMO▼PFS and vials are listed on the PBS for nAMD, DMO and RVO. Refer to PBS Schedule for full authority information.

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

 

Disclaimer:

This is intended for the healthcare professionals outside of the USA and the UK. The speakers have been invited to provide their own independent professional opinion without any expectation of emphasis or bias towards Roche products. 

 

Presentations may include information on compounds that are not registered or indicated by the Therapeutic Goods Administration (TGA) for the conditions being discussed. You are advised to visit www.roche-australia.com/productinfo for the full Product Information and TGA approved indications of discussed Roche products and the TGA website for other products.

 

Roche product vigilance: To report a suspected side effect or product complaint associated with the use of a Roche product, visit www.medinfo.roche.com/australia or contact Roche Patient Safety at australia.safety@roche.com.

 

Confidentiality:

This message is intended only for the use of the named recipient(s) and may contain confidential and/or proprietary information. If you are not the intended recipient, please contact the sender and delete this message. Any unauthorised use of the information contained in this message is prohibited.

 

If you would like to access your personal information held by Roche; request an amendment or correction of your personal information held by Roche; ask us to remove your personal information from our system; ask us about, or request a copy of, our Privacy Policy; or make a complaint, please email us at australia.privacy-request@roche.com or write to the Privacy Officer, Roche Products Pty Limited, Level 8, 30-34 Hickson Road, Sydney NSW 2000.

 

Further information is available on request from Roche Products Pty Limited, ABN 70 000 132 865, Level 8, 30–34 Hickson Road, Sydney NSW 2000. Medical Information: www.medinfo.roche.com/australia or 1800 233 950.

 

®Registered Trademark. M-AU-00005271. Prepared June 2026.

 

Roche Products Pty Limited

ABN 70 000 132 865, Level 8,

30–34 Hickson Road, 

Sydney NSW 2000

Are you sure?
Restricted

Bookmarking is available only for logged-in users.

Sign up Log in